DHR · Danaher Corp

206.78−4.25  (−2.01%)

Price

Snapshot

50 fields · last close
Market Cap$148.4B
P/E36.77
Float626.6M
Beta0.79
Volatility19.8%
ExchangeNYSE
SectorLife Sciences Tools & Services
Cap tierLarge cap
Macro sensitivityModerate
Clavix score75
Price206.78
Change−2.01%
Prev Close211.03
Open210.51
Day Low206.05
Day High213.13
Avg Vol3
Avg $ Vol$698.1M
52W High242.80
52W Low160.93
52W Pos56.0%
From High−14.84%
From Low+28.49%
Max DD 1Y−33.11%
Spread0.10%
LiquidityDeep
SMA 20−1.58%
SMA 50+2.70%
SMA 200+2.03%
RSI (14)55.0
Vol 30D28.0%
Vol 90D36.1%
1Y Range161–243
Daily bars507
Perf Week−2.16%
Perf Month+5.69%
Perf Quarter+13.07%
Perf Half Y+7.94%
Perf Year+6.03%
Perf YTD−10.25%
Prev Day−2.01%
ClavixB
Debt / Eq0.35
Curr Ratio1.87
Int Cover13.3×
FCF Margin21.4%
Rev Growth+0.0%
ProfitProfitable
LeverageLow
Sector rank6 / 19

What DHR does

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.

The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.

The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.

Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Clavix risk grade

regraded every trading day
B75/100

DHR grades B, 75 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (60, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 6 of 19 in Life Sciences Tools & Services by Clavix score.

PriceMacroSectorNewsFinancial

How rough the ride is

DHRLife Sciences Tools & Services median
Betavs the overall market · lower is steadier0.791.19
Volatilityannualized19.8%29.7%
Max drawdown, past yearworst peak-to-trough fall−33.1%
Typical daily movemedian absolute daily change1.04%
Days beyond ±3%of the last 252 sessions208%

How its days are spread

Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.

52-week range

DHR
211.03

The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.

Drawdown from the 1-year peak

DHR

Percent below the running high over the last 12 months. Zero is a fresh high.

Market sensitivity

DHRLife Sciences Tools & Services median
Beta to the markethow much it swings with the S&P 500 · lower is safer0.791.19
Macro sensitivityrate, dollar and credit exposure bucketModerateModerate47% of 19

Where it sits on the macro scale

Low 1Moderate 9High 6Very High 3

Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.

Where it ranks in its sector

Sector
Life Sciences Tools & Services19 companies ranked
DHR
#6 of 19

Rank by Clavix score within the sector. Right is the top of the sector.

Price performance

DHR
1 week−2.2%
1 month+5.7%
Year to date−10.3%
1 year+6.0%

Context for the rank, not itself a risk measure.

Recent coverage, scored

DHR
Articles scoredthe most recent scored coverage, up to 3030since 16 Jul
Average score0 most bearish, 100 most bullish57
Bullish · bearisharticles above 60 · below 4017 · 5
Directionarticles whose tone is improving vs worsening17 ↑ 5 ↓

Where the article scores land

Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.

Balance sheet, against the sector

Debt / equityTotal debt vs shareholder equity · lower is stronger
0.35sector median 0.51 · 19 names
Current ratioShort-term assets vs liabilities · higher is stronger
1.87sector median 1.89 · 19 names
FCF marginFree cash flow as a share of revenue · higher is stronger
21.4%sector median 19.5% · 18 names
Interest coverageOperating income vs interest expense · higher is stronger
13.3×sector median 3.5× · 19 names

The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.

Growth

DHR
Revenue growthyear over year+0.0%

Financial Health is shown but does not count toward the grade. Why

0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.

Against Life Sciences Tools & Services

19 companies
MetricDHRSector spreadMedian
Beta0.79
1.19
Volatility19.8%
29.7%
P/E36.77
36.77
Debt / equity0.35
0.51
Current ratio1.87
1.89
FCF margin21.4%
19.5%
Interest coverage13.3×
3.5×

Recent news

most recent scored articles · the chip is the article’s score · click to open

Man Group plc disclosed in a recent SEC Form 13F filing that it opened a new position in Danaher Corporation during the second quarter, buying 428,118 shares valued at roughly $81.55 million.

Source tickerreport.com Significance moderate Impact financial impact Risk improving

Read the article →

Danaher's Biotechnology segment is growing, supported by demand from China, strength in bioprocessing (the equipment used to manufacture biologic drugs), and improving discovery markets, though regional headwinds are partially offsetting that growth.

Source Zacks Investment Research Significance minor Impact sector Risk improving

Read the article →

B. Metzler seel. Sohn & Co. AG disclosed in its most recent 13F filing (a quarterly SEC report of investment holdings) that it acquired a new position in Danaher Corporation in the second quarter, buying 28,281 shares worth about $20.36 million. The article body is cut off after this detail.

Source marketbeat.com Significance moderate Impact financial impact Risk improving

Read the article →

A Delaware jury awarded Beckman Coulter roughly $36 million in damages after finding that Cytek Biosciences infringed a Beckman Coulter patent covering technology that quickly analyzes single cells.

Source law360.com Significance moderate Impact regulatory Risk improving

Read the article →

Madison Asset Management bought a new position in Danaher, acquiring 448,611 shares worth about $85.45 million in the second quarter, making DHR roughly 1.0% of its portfolio.

Source tickerreport.com Significance moderate Impact financial impact Risk improving

Read the article →

Nearest peers by size

Life Sciences Tools & Services
TickerCompanyGradeMkt capP/EBeta
TMOThermo Fisher Scientific IncB+$228.7B32.510.87Compare
IQVIQVIA Holdings IncB-$44.71B32.101.18Compare
AAgilent Technologies IncB$42.28B29.651.27Compare
WATWaters CorpB$37.34B243.611.19Compare
ILMNIllumina IncB-$33.47B39.201.48Compare
MTDMettler-toledo International IncB+$27.17B29.971.21Compare
WSTWest Pharmaceutical Services IncB+$23.90B42.691.16Compare
MEDPMedpace Holdings IncB-$16.56B33.641.13Compare

You just read one holding. Clavix reads the whole portfolio.

Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.